Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Araghchi: Iran adopted a constructive approach in its engagement to ensure the European Union and the E3 fully honored their commitments and lifted all sanctions.
Araghchi: After a year of Iran’s full compliance with the agreement, it began implementing gradual, proportionate, and reversible compensatory steps in accordance with its recognized rights under the deal.
Araghchi: Iran demonstrated the utmost restraint in the face of repeated and fundamental violations and made extensive efforts to restore balance and preserve the agreement.
In his letter, Araghchi stated: The E3 failed to fulfill their obligations and instead imposed additional illegal sanctions on Iranian individuals and institutions.
Araghchi: These coercive measures constituted a grave violation of international law and the UN Charter, causing severe disruption in the implementation of the agreement.
Araghchi: Washington initially refrained from fulfilling its commitments, then withdrew from the agreement, reimposed its illegal and unilateral sanctions, and even expanded them.
Araghchi: UN Security Council Resolution 2231 has expired and fully ceased to be in effect as of today, in accordance with its explicit provisions.
Iranian Foreign Ministry: Reimposing sanctions on Iran is illegal
Occupied Palestine: Israeli occupation forces raid homes during a raid on the village of Al-Burj, south of al-Khalil
Hamas spokesperson Hazem Qassem: The movement remains committed to implementing the ceasefire agreement through the handover of another Israeli captive’s body earlier this evening

Positive results, risks reported in Alzheimer's new drug

  • By Al Mayadeen English
  • Source: Agencies
  • 30 Nov 2022 12:55
3 Min Read

Full data showing that a new drug can slow cognitive decline in Alzheimer's patients was released by experts.

  • x
  • Deaths were reported at approximately the same rate in both arms of the trial of the drug, which was developed by firms Biogen and Eisai.Source:AFP
    Deaths were reported at approximately the same rate in both arms of the trial of the drug (AFP)

Experts applauded full data released on Wednesday showing that a new drug can slow cognitive decline in Alzheimer's patients but cautioned that the improvements were comparatively small and the treatment could have serious side effects.

Preliminary data from a lecanemab trial revealed that it slowed cognitive decline by 27% over an 18-month period.

The full trial data, published in the New England Journal of Medicine, expands on those findings while also raising concerns about the frequency of "adverse effects", such as brain bleeds and swelling.

According to the findings, 17.3% of patients given the drug experienced brain bleeds, compared to 9% of those having a placebo. In addition, 12.6% of those taking the drug experienced brain swelling, compared to 1.7% in the placebo group.

Read next: New Blood Test Allows for Early Detection of Alzheimer Symptoms

Deaths were reported at roughly the same rate in both arms of the drug trial, which was developed by Biogen and Eisai.

The findings were widely applauded by researchers and advocates for dementia patients, including Bart De Strooper, director of the UK Dementia Research Institute. "This is the first drug that provides a real treatment option for people with Alzheimer's," he said.

Related News

Air pollution linked to increased dementia risk: Harvard report

19-year-old Chinese man becomes youngest patient with Alzheimer's

"While the clinical benefits appear somewhat limited, it can be expected that they will become more apparent if the drug is administered over a longer time period."

Longer trials needed 

Regarding Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Lecanemab works by targeting amyloid, and according to De Strooper, the drug not only cleared it but also had "beneficial effects on other hallmarks of Alzheimer's, including tau."

The phase three trial lasted for 18 months and involved nearly 1,800 people who were randomly assigned to either the drug or a placebo.

They were evaluated using an Alzheimer's disease clinical scale that measures cognition and function, as well as changes in amyloid levels and other indicators. However, Tara Spires-Jones, programme lead at the UK Dementia Research Institute, noted that "there is not an accepted definition of clinically meaningful effects in the cognitive test they used."

"It is not clear yet whether the modest reduction in decline will make a big difference to people living with dementia. Longer trials will be needed to be sure that the benefits of this treatment outweigh the risks," she added.

Additionally, the drug only targets those in the early stages of the disease with a certain level of amyloid buildup, limiting the number of people who could potentially benefit from the treatment. And as Alzheimer's is not always caught quickly, some experts said an overhaul in early diagnosis would be needed to ensure more people could benefit.

Previously, Biogen and Eisai put the Alzheimer's drug Aduhelm on the market, but there was significant controversy over the evidence that it worked, and its approval resulted in the resignations of three high-level FDA officials.

  • Alzheimer
  • Lecanemab
  • United Kingdom
  • Alzheimer's Disease

Most Read

Iran strikes secret Israeli-US bunker under Tel Aviv high-rise

Tel Aviv high-rise struck by Iran hid Site 81, secret US-Israeli base

  • Politics
  • 14 Oct 2025
Palestinian journalist Saleh al-Jaafarawi in an undated image in Gaza, occupied Palestine (Social media)

Gaza Palestinian journalist Saleh al-Jafarawi killed by collaborators

  • Politics
  • 12 Oct 2025
drop site

New report details extensive Israeli arson in Gaza after ceasefire

  • Politics
  • 13 Oct 2025
Illustration of fists breaking shackles, representing the liberation of Palestinian detainees from Israeli prisons. (Illustrated by: AL Mayadeen English/Batoul Chamas)

4 prominent Palestinian detainees to be freed: Who are they?

  • Palestine
  • 13 Oct 2025

Coverage

All
War on Gaza

Read Next

All
Residents remove debris from a house damaged by Wednesday's two drone strikes, in Kabul, Afghanistan, Thursday, Oct. 16, 2025 (AP)
Politics

Afghanistan-Pakistan negotiations to begin in Doha: Exclusive

Palestine Action wins court fight to challenge UK terror ban
Politics

Palestine Action wins court fight to challenge UK 'terror' ban

John Bolton surrenders after classified documents indictment
Politics

John Bolton turns himself in after classified documents indictment

GSF, GMTG slams EU over complicity in Gaza genocide
Politics

GSF, GMTG slam EU over complicity in crimes against Palestinians

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS